Year |
Citation |
Score |
2016 |
Soler DC, Young AB, Fiessinger L, Galimberti F, Debanne S, Groft S, McCormick TS, Cooper KD. Increased, but functionally impaired, CD14(+) HLA-DR(neg/low) Myeloid-Derived Suppressor Cells in psoriasis; a mechanism of dysregulated T cells. The Journal of Investigative Dermatology. PMID 26807516 DOI: 10.1016/J.Jid.2015.12.036 |
0.31 |
|
2016 |
Galimberti F, Fernandez AP. Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis? Clinical and Experimental Dermatology. 41: 413-6. PMID 26800651 DOI: 10.1111/Ced.12793 |
0.308 |
|
2015 |
Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, Mustachio LM, Galimberti F, Ravi S, DeCastro A, Lu Y, et al. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Research. 75: 2029-38. PMID 25808870 DOI: 10.1158/0008-5472.Can-14-1494 |
0.741 |
|
2014 |
Busch AM, Galimberti F, Nehls KE, Roengvoraphoj M, Sekula D, Li B, Guo Y, Direnzo J, Fiering SN, Spinella MJ, Robbins DJ, Memoli VA, Freemantle SJ, Dmitrovsky E. All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15: 463-72. PMID 24496080 DOI: 10.4161/Cbt.27821 |
0.798 |
|
2014 |
Hu S, Danilov AV, Godek KM, Orr B, Tafe LJ, Memoli VA, Galimberti F, Ravi S, DeCastro AJ, Lu Y, Mustachio LM, Sekula DJ, Andrew AS, Freemantle SJ, Compton DA, et al. Abstract 4549: CDK2 inhibition causes anaphase catastrophe through the centrosomal protein CP110 Cancer Research. 74: 4549-4549. DOI: 10.1158/1538-7445.Am2014-4549 |
0.735 |
|
2013 |
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Molecular Cancer Therapeutics. 12: 1545-55. PMID 23686769 DOI: 10.1158/1535-7163.Mct-12-0933 |
0.825 |
|
2013 |
Rodriguez-Blanco J, Schilling NS, Tokhunts R, Giambelli C, Long J, Liang Fei D, Singh S, Black KE, Wang Z, Galimberti F, Bejarano PA, Elliot S, Glassberg MK, Nguyen DM, Lockwood WW, et al. The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene. 32: 2335-45. PMID 22733134 DOI: 10.1038/Onc.2012.243 |
0.717 |
|
2013 |
Dragnev K, Beumer J, Anyang B, Ma T, Galimberti F, Erkmen C, Nugent W, Rigas J, Abraham K, Johnstone D, Memoli V, Dmitrovsky E. A Proof-of-Principle Histone Deacetylase Inhibitor Trial in Resectable Aerodigestive Tract Cancer: Intratumoral Drug Levels and Biomarker Responses Annals of Oncology. 24: i7. DOI: 10.1093/Annonc/Mdt042.14 |
0.589 |
|
2012 |
Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, Dragnev KH, Liu F, Johnson KC, Guo Y, Freemantle SJ, Andrew AS, Greninger P, Robbins DJ, Settleman J, et al. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61. PMID 22923130 DOI: 10.3892/Ijo.2012.1599 |
0.799 |
|
2012 |
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E. Evidence for the ubiquitin protease UBP43 as an antineoplastic target. Molecular Cancer Therapeutics. 11: 1968-77. PMID 22752428 DOI: 10.1158/1535-7163.Mct-12-0248 |
0.815 |
|
2012 |
Dragnev KH, Beumer JH, Anyang B, Ma T, Galimberti F, Erkmen CP, Nugent W, Rigas JR, Abraham K, Johnstone D, Memoli V, Dmitrovsky E. Vorinostat (V) intratumoral levels and biomarker response in a window of opportunity trial in patients with resectable aerodigestive tract cancer. Journal of Clinical Oncology. 30: 7022-7022. DOI: 10.1200/Jco.2012.30.15_Suppl.7022 |
0.636 |
|
2011 |
Dragnev KH, Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas JR, Johnstone D, Frandsen A, Simeone S, Czum J, Li H, DiRenzo J, Freemantle S, Dmitrovsky E. A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7062. PMID 28020374 DOI: 10.1200/Jco.2011.29.15_Suppl.7062 |
0.735 |
|
2011 |
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prevention Research (Philadelphia, Pa.). 4: 818-28. PMID 21636548 DOI: 10.1158/1940-6207.Capr-10-0376 |
0.82 |
|
2011 |
Galimberti F, Thompson SL, Ravi S, Compton DA, Dmitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1218-22. PMID 21288923 DOI: 10.1158/1078-0432.Ccr-10-1178 |
0.647 |
|
2011 |
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer MA, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, et al. Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-412 |
0.82 |
|
2011 |
Ma T, Galimberti F, Erkmen CP, Memoli V, Nugent W, Rigas J, Johnstone D, Li H, DiRenzo J, Freemantle S, Dragnev K, Dmitrovsky E. Abstract 342: Murine transgenic lung cancer models guide a proof of principle histone deacetylase inhibitor trial in lung cancer patients Cancer Research. 71: 342-342. DOI: 10.1158/1538-7445.Am2011-342 |
0.742 |
|
2011 |
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Galimberti F, Ma T, Feng Q, Andrew AS, Sekula D, Freemantle S, Memoli V, Dmitrovsky E. Abstract 1655: The ubiquitin protease UBP43 is a target for lung cancer therapy and prevention Cancer Research. 71: 1655-1655. DOI: 10.1158/1538-7445.Am2011-1655 |
0.829 |
|
2011 |
Galimberti F, Busch A, Chinyengetere F, Ma T, Sekula D, Memoli V, Dragnev K, Liu F, Andrew AS, Greninger P, Robbins D, Settleman J, Benes C, Dmitrovsky E. Abstract 1615: Gene expression profile predicts response to smoothened inhibitors in epithelial cancers Cancer Research. 71: 1615-1615. DOI: 10.1158/1538-7445.Am2011-1615 |
0.817 |
|
2010 |
Guo Y, Dolinko AV, Chinyengetere F, Stanton B, Bomberger JM, Demidenko E, Zhou DC, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Freemantle S, Dmitrovsky E. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARα and inhibits the growth of acute promyelocytic leukemia. Cancer Research. 70: 9875-85. PMID 20935222 DOI: 10.1158/0008-5472.Can-10-1100 |
0.78 |
|
2010 |
Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 109-20. PMID 20028770 DOI: 10.1158/1078-0432.Ccr-09-2151 |
0.687 |
|
2010 |
Guo Y, Dolinko A, Chinyengetere F, Bomberger J, Gallagher R, Ma T, Galimberti F, Liu X, Sekula D, Busch A, Freemantle S, Dmitrovsky E. Abstract 1594: Targeting UBP43 for repression destabilizes PML/RARα and inhibits acute promyelocytic leukemia growth Cancer Research. 70: 1594-1594. DOI: 10.1158/1538-7445.Am10-1594 |
0.762 |
|
2009 |
Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Yan M, Fiering S, Memoli V, Li H, Direnzo J, Korc M, Cole CN, Bak M, Kauppinen S, et al. Uncovering growth-Suppressive micro rNAs in lung cancer Clinical Cancer Research. 15: 1177-1183. PMID 19228723 DOI: 10.1158/1078-0432.Ccr-08-1355 |
0.645 |
|
2008 |
Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics. 7: 3780-8. PMID 19074853 DOI: 10.1158/1535-7163.Mct-08-0753 |
0.67 |
|
2007 |
Freemantle SJ, Liu X, Feng Q, Galimberti F, Blumen S, Sekula D, Kitareewan S, Dragnev KH, Dmitrovsky E. Cyclin degradation for cancer therapy and chemoprevention. Journal of Cellular Biochemistry. 102: 869-77. PMID 17868090 DOI: 10.1002/Jcb.21519 |
0.673 |
|
Show low-probability matches. |